IsoRay Announces "Long-term PSA Outcomes in a Single Institution, Prospective Randomized Cesium-131 / Iodine-125 Permanent Prostate Brachytherapy Trial" Poster Presentation at 2017 Annual American Society for Radiation Oncology (ASTRO) Conference
9-Year Study Demonstrates Durable Positive Outcomes and Statistically Identical Results of Cesium-131
RICHLAND, Wash., Sept. 25, 2017 -- (Healthcare Sales & Marketing Network) -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator ... Devices, Oncology IsoRay, brachytherapy, radiotherapy, cesium, iodine, prostate cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Brachytherapy | Cancer | Cancer & Oncology | Conferences | Iodine | Marketing | Pharmaceuticals | Prostate Cancer | Statistics | Study